TNFR2 Sex Differences and EAE
TNFR2 性别差异和 EAE
基本信息
- 批准号:10384115
- 负责人:
- 金额:$ 37.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-01 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:ATF6 geneAgonistCell DeathCellsCoupledDataDiseaseDisease ProgressionExperimental Autoimmune EncephalomyelitisFemaleGenesGeneticGoalsGonadal Steroid HormonesImmune responseIn VitroInflammationInflammatory ResponseKnockout MiceLigationLinkMediatingMediator of activation proteinMotorMultiple SclerosisMusMyelinNatural regenerationNerve DegenerationNeuraxisNeuroimmuneNeuroimmune systemNeurologicNeuronsOligodendrogliaPathologyPathway interactionsPharmacologyPhysiologicalPredispositionProcessProtein BiosynthesisProteinsPublishingQuality ControlRecovery of FunctionRegenerative responseRoleSeriesSex BiasSex ChromosomesSex DifferencesSignal TransductionStressTNFRSF1B geneTestingTherapeuticTherapeutic EffectWorkXBP1 genebaseburden of illnesshormonal signalsin vivomalemotor disordermotor function improvementmotor impairmentmotor recoveryneuroinflammationneuropathologynovelpainful neuropathyprogramsremyelinationrepairedresponsesextranscriptome sequencing
项目摘要
Abstract
The susceptibility to Multiple Sclerosis (MS) is believed to be due in part to neuroinflammation
and disease burden linked to neurodegeneration. It is well established that females have a more robust
immune response than males however, neurodegeneration and disease progression are more sever in
males. Thus, in the context of MS, this raises an intriguing question. Do females, by virtue of having a
more robust inflammatory responses, have endogenous protection/repair mechanisms to protect the
central nervous system (CNS) from inflammation induced pathology, that males do not have or that are
not as effective in males? This proposal is based upon extensive preliminary and published data
demonstrating that tmTNF/TNFR2 signaling in females, but not males, significantly improves motor
function and reduces neuropathology in EAE by activating endogenous repair programs in neurons and
oligodendrocytes. Based upon these and other results, our first experimental goal is to interrogate sex
differences in tmTNF/TNFR2 induced improvements in motor function and neuropathology. Further, we
have very novel pharmacological and genetic data that ligation of TNFR2 on both neurons and
oligodendrocytes induce regenerative responses, through IRE1-dependent mechanisms. Based upon
these and additional data our second experimental goal is to investigate the intersection between
TNFR2/IRE1 signaling and to determine if the therapeutic effects of TNFR2 activation are dependent
upon IRE1 activation. These goals will be tested in the following aims:
Specific Aim 1: Investigate the sex-specific effects of tmTNF/TNFR2 signaling in the improvement of
motor function and neuropathology.
A) We will investigate the role of sex hormones in tmTNF/TNFR2 signaling in the improvement of motor
function and neuropathology in male and female mice.
B) We will investigate the role of sex chromosomes in tmTNF/TNFR2 signaling in the improvement of motor
function and neuropathology in male and female mice.
Specific Aim 2: Investigate TNFR2 induced endogenous repair mechanisms in male and female mice.
A) We will interrogate TNFR2 induced endogenous repair mechanisms oligodendrocytes and determine if
they are required for motor recovery in females.
B) We will interrogate TNFR2 induced endogenous repair mechanisms neurons and determine if they are
required for motor recovery in females, in vivo and in vitro.
抽象的
多发性硬化症 (MS) 的易感性被认为部分是由于神经炎症造成的
以及与神经退行性变相关的疾病负担。众所周知,女性拥有更强健的体质
免疫反应比男性强,然而,神经退行性变和疾病进展在男性中更为严重
男性。因此,在多发性硬化症的背景下,这提出了一个有趣的问题。做女性,凭借拥有
更强烈的炎症反应,具有内源性保护/修复机制来保护
炎症引起的病理学中枢神经系统(CNS),男性没有或有
对男性没有那么有效吗?该提案基于广泛的初步和已发布的数据
证明女性而非男性中的 tmTNF/TNFR2 信号传导可显着改善运动能力
通过激活神经元中的内源性修复程序来发挥功能并减少 EAE 中的神经病理学
少突胶质细胞。基于这些和其他结果,我们的第一个实验目标是询问性别
tmTNF/TNFR2 的差异导致运动功能和神经病理学的改善。此外,我们
具有非常新颖的药理学和遗传数据,即 TNFR2 在神经元和
少突胶质细胞通过 IRE1 依赖性机制诱导再生反应。基于
这些和其他数据我们的第二个实验目标是研究之间的交叉点
TNFR2/IRE1 信号转导并确定 TNFR2 激活的治疗效果是否具有依赖性
IRE1 激活后。这些目标将在以下目标中进行测试:
具体目标 1:研究 tmTNF/TNFR2 信号传导在改善
运动功能和神经病理学。
A) 我们将研究性激素在 tmTNF/TNFR2 信号传导中对运动能力改善的作用
雄性和雌性小鼠的功能和神经病理学。
B) 我们将研究性染色体在 tmTNF/TNFR2 信号传导中在改善运动能力方面的作用
雄性和雌性小鼠的功能和神经病理学。
具体目标 2:研究 TNFR2 在雄性和雌性小鼠中诱导的内源性修复机制。
A) 我们将询问 TNFR2 诱导的少突胶质细胞内源性修复机制,并确定是否
它们是女性运动恢复所必需的。
B) 我们将询问 TNFR2 诱导的神经元内源性修复机制,并确定它们是否
女性体内和体外运动恢复所需的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Roland Bethea其他文献
John Roland Bethea的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Roland Bethea', 18)}}的其他基金
SCI-induced deficits in antiviral immunity: The role of sTNF.
SCI 引起的抗病毒免疫缺陷:sTNF 的作用。
- 批准号:
10207806 - 财政年份:2019
- 资助金额:
$ 37.88万 - 项目类别:
SCI-induced deficits in antiviral immunity: The role of sTNF.
SCI 引起的抗病毒免疫缺陷:sTNF 的作用。
- 批准号:
10019418 - 财政年份:2019
- 资助金额:
$ 37.88万 - 项目类别:
SCI-induced deficits in antiviral immunity: The role of sTNF.
SCI 引起的抗病毒免疫缺陷:sTNF 的作用。
- 批准号:
10441446 - 财政年份:2019
- 资助金额:
$ 37.88万 - 项目类别:
SCI-induced deficits in antiviral immunity: The role of sTNF.
SCI 引起的抗病毒免疫缺陷:sTNF 的作用。
- 批准号:
10657427 - 财政年份:2019
- 资助金额:
$ 37.88万 - 项目类别:
Soluble TNFa in the development of autonomic dysreflexia after spinal cord injury
可溶性 TNFa 在脊髓损伤后自主神经反射异常发展中的作用
- 批准号:
10386794 - 财政年份:2018
- 资助金额:
$ 37.88万 - 项目类别:
Soluble TNFa in the development of autonomic dysreflexia after spinal cord injury
可溶性 TNFa 在脊髓损伤后自主神经反射异常发展中的作用
- 批准号:
9902562 - 财政年份:2018
- 资助金额:
$ 37.88万 - 项目类别:
Enhancing supraspinal plasticity to improve functional recovery after SCI
增强脊髓上可塑性以改善 SCI 后的功能恢复
- 批准号:
9976601 - 财政年份:2017
- 资助金额:
$ 37.88万 - 项目类别:
Enhancing supraspinal plasticity to improve functional recovery after SCI
增强脊髓上可塑性以改善 SCI 后的功能恢复
- 批准号:
9193741 - 财政年份:2016
- 资助金额:
$ 37.88万 - 项目类别:
Astrocytes Play a Critical Role in the Pathology of EAE
星形胶质细胞在 EAE 病理学中发挥关键作用
- 批准号:
8824782 - 财政年份:2009
- 资助金额:
$ 37.88万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 37.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 37.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




